Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) Receives Consensus Rating of “Buy” from Analysts

Shares of Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) have received an average rating of “Buy” from the thirteen research firms that are presently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, ten have issued a buy rating and two have issued a strong buy rating on the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $23.10.

A number of equities analysts recently commented on CMPS shares. Raymond James Financial reiterated a “buy” rating on shares of Compass Pathways in a research report on Friday, May 22nd. Maxim Group lifted their price objective on Compass Pathways from $12.00 to $20.00 and gave the company a “buy” rating in a research report on Friday, May 15th. B. Riley Financial started coverage on Compass Pathways in a report on Friday, April 24th. They set a “buy” rating and a $17.00 target price on the stock. Jefferies Financial Group raised Compass Pathways to a “strong-buy” rating in a research report on Tuesday, May 5th. Finally, BTIG Research restated a “buy” rating and set a $14.00 target price on shares of Compass Pathways in a report on Wednesday, May 13th.

Compass Pathways Stock Performance

Shares of CMPS stock opened at $14.82 on Tuesday. The stock has a market capitalization of $2.00 billion, a P/E ratio of -4.70 and a beta of 2.50. The company has a current ratio of 3.32, a quick ratio of 3.32 and a debt-to-equity ratio of 0.15. The firm’s 50 day moving average is $10.98 and its 200 day moving average is $8.12. Compass Pathways has a 12 month low of $2.61 and a 12 month high of $14.94.

Compass Pathways (NASDAQ:CMPS) last issued its earnings results on Wednesday, May 13th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.45) by $0.15. On average, sell-side analysts anticipate that Compass Pathways will post -1.24 earnings per share for the current year.

Hedge Funds Weigh In On Compass Pathways

A number of institutional investors and hedge funds have recently modified their holdings of the company. EverSource Wealth Advisors LLC raised its holdings in Compass Pathways by 67.7% in the 1st quarter. EverSource Wealth Advisors LLC now owns 4,754 shares of the company’s stock worth $26,000 after purchasing an additional 1,920 shares during the period. Persistent Asset Partners Ltd bought a new position in Compass Pathways in the fourth quarter worth approximately $38,000. Parallel Advisors LLC raised its stake in Compass Pathways by 8,450.6% in the first quarter. Parallel Advisors LLC now owns 7,268 shares of the company’s stock worth $40,000 after buying an additional 7,183 shares in the last quarter. Advisory Services Network LLC acquired a new position in shares of Compass Pathways in the 3rd quarter valued at $41,000. Finally, North Star Investment Management Corp. increased its position in shares of Compass Pathways by 1,354.0% in the 1st quarter. North Star Investment Management Corp. now owns 7,517 shares of the company’s stock valued at $42,000 after acquiring an additional 7,000 shares during the period. 46.19% of the stock is currently owned by hedge funds and other institutional investors.

Compass Pathways Company Profile

Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.